Overview

Lapatinib+Vinorelbine vs Vinorelbine HER2 Positive Metastatic Breast Cancer Progressed After Lapatinib/Trastuzumab

Status:
Unknown status

Trial end date:
2017-12-01

Target enrollment:

Participant gender:

Summary

The investigators address the clinical efficacy of continuing lapatinib treatment combined with vinorelbine after the progression of both trastuzumab and lapatinib treatment compared with vinorelbine alone in HER2 positive metastatic breast cancer patients.

Phase:

Phase 2

Details

Lead Sponsor:

National Cancer Center, Korea

Collaborators:

Asan Medical Center
Chung-Ang University
Korea University Anam Hospital
Samsung Medical Center
Seoul National University Bundang Hospital
Seoul National University Hospital

Treatments:

Lapatinib
Trastuzumab
Vinblastine
Vinorelbine